10
Views
2
CrossRef citations to date
0
Altmetric
Review Of Two Scandinavian Theses

Physiology and pathophysiology of GIP: A review

&
Pages 571-579 | Published online: 29 Mar 2011

References

  • Moore B, Edic E S, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochcm J 1906; 1: 28–38
  • La Barre J. Sur les possibilites ďun trait-ment du diabetes par ľincretine. Bull Acad R Med Belg 1932; 12: 620–34
  • Yalow R S, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157–75
  • Elrick H, Stimmler L, Hlad CJ, Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol 1964; 24: 1076–82
  • McLntyre N, Holdsworth C D, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; ii: 20–1
  • Brown J C, Dryburgh JR. A gastric inhibitory polypeptide II: the complete amino acid sequence. Can J Biochem 1971; 49: 867–72
  • Dupré J, Ross S A, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826–8
  • Andersen D K, Elahi D, Brown J C, Tobin J D, Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 1978; 62: 152–61
  • Brown J C, Pederson RA. GI hormones and insulin secretion. Endocrinology Proceedings of the Fifth International Congress of Endocrinology., VHT James. Excerpta Medica, Amsterdam 1976; vol 2: 568–70
  • Brown J C, Dryburgh J R, Ross S A, Dupre J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 1975; 31: 487–532
  • Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988; 9: 122–34
  • Groop P-H. The relationship between gastric inhibitory polypeptide (GIP) and beta-cell function in man. Comment Phys-Mat Dissert 1989; 104: 1–64
  • Brown J C, McIntosh C HS, Muller M, Otte S C, Pederson RA. GIP and the entero-insular axis. Gut Peptides, A Miyoshi. Elsevier/North-Holland, New York 1979; 162–8
  • Krarup T, Hoist J J, Larsen KL. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 1985; 249: E195–200
  • Krarup T, Hoist JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984; 9: 35–46
  • Krarup T, Hoist J J, Madsbad S. Heterogeneity of immunoreactive gastric inhibitory Y polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. Acta Endocrinol 1987; 114: 74–83
  • Krarup T, Hoist J J, Knuhtsen S, Moody A J, Nielsen OV. Effect of porcine 8000 dalton immunoreactive gastric inhibitory polypeptide on the isolated perfused pig pancreas. Diabetes 1987; 36: 7A, abstract
  • Otte S C, Mutt V, McIntosh C HS, Brown JC. Purification and amino acid composition of an 8000 dalton immunoreactive form of GIP. Dig Dis Sci 1984; 29: 63S, Suppl. abstract
  • Moody A J, Thim L, Valverde I. The isolation and sequencing of human gastric inhibitory peptide (GIP). FEBS Lett 1984; 172: 142–8
  • Jörnvall H, Carlquist M, Kwauk S, Otte S C, McIntosh C HS, Brown J C, Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 1981; 123: 205–10
  • Carlquist M, Maletti M, Jörnvall H, Mutt V. Bovine gastric inhibitory polypeptide (GIP), isolated by using a receptor assay, is different from the porcine hormone. Dig Dis Sci 1984; 29: 15S, Suppl. abstract
  • Jorde R, Amland P F, Burhol P G, Giercksky K-E. What are 'physiological' plasma GIP levels in man after intravenous infusion of porcine GIP?. Scand J Gastroenterol 1985; 20: 268–71
  • Amland P F, Jorde R, Revhaug A, Myhre E SP, Burhol P G, Giercksky K-E. Fasting and postprandial GIP values in pigs, rats, dogs, and man measured with five different GIP antisera. Scand J Gastroenterol 1984; 19: 1095–8
  • Jorde R, Burhol P G, Waldum H L, Schulz T B, Lygren I, Florholmen J. Diurnal variation of plasma gastric inhibitory polypeptide in man. Scand J Gastroenterol 1980; 15: 617–9
  • Jones I R, Owens D R, Luzio S, Hayes TM. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Horm Metabol Res 1989; 21: 23–6
  • Beck B. Gastric inhibitory polypeptide: a gut hormone with anabolic functions. J Mol Endocrinol 1989; 2: 169–74
  • Taylor I L, Feldman M. Effect of cephalic-vagal stimulation on insulin, gastric inhibitory polypeptide, and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 1982; 55: 1114–7
  • Schwartz TW. Pancreatic polypeptide: A hormone under vagal control. Gastroenterology 1983; 85: 1411–25
  • Lorentzen M, Madsbad S, Kehlet H, Tronier B. Effect of sham-feeding on glucose tolerance and insulin secretion. Acta Endocrinol 1987; 115: 84–6
  • Jensen S L, Nielsen O V, Kühl C. The enteral insulin-stimulation after pancreas transplantation in the pig. Diabetologia 1976; 12: 617–20
  • Clark J DA, Wheatley T, Brons I GM, Bloom S R, Calne RY. Studies of the entero-insular axis following pancreas transplantation in man: neural or hormonal control?. Diab Med 1989; 6: 813–7
  • Faber O K, Kehlet H, Madsbad S, Binder C. Kinetics of human C-peptide in man. Diabetes 1978; 27: 207–9, suppl. 1
  • Polonsky K S, Rubinstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetologia 1984; 33: 486–94
  • Madsbad S, Kehlet H, Hilsted J, Tronier B. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 1983; 32: 436–8
  • Shuster L T, Go V LW, Rizza R A, O'Brien P C, Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 1988; 37: 200–3
  • Nauck M A, Homberger E, Siegel E G, Allen R C, Eaton R P, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492–8
  • Groop P-H, Groop L, Tötterman K J, Fyhrquist F. Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy. Scand J Clin Lab Invest 1986; 46: 505–10
  • Groop P-H, Groop L, Tötterman K J, Fyhrquist F. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol 1986; 112: 361–6
  • Hanks J B, Anderson D K, Wise J E, Putnam W S, Meyers W C, Jones RS. The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 1984; 115: 1011–8
  • Kreyman B, Williams G, Ghatei M A, Bloom SR. Glucagon-like peptide-1. 7–36: a physiological incretin in man. Lancet 1987; ii: 1300–3
  • Ørskov C, Jeppesen J, Madsbad S, Hoist JJ. Proglucagon products in plasma of non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginin. J Clin Invest 1991; 87: 415–23
  • Creutzfeldt W, Ebert R. Release of gastric inhibitory polypeptide (GIP) to a test meal under normal and pathological conditions in man. Diabetes, JS. Bajaj. Excerpta Medica. 1977; 63–75
  • Krarup T, Madsbad Regeur L, Alberti K GMM, Faber O K, Kurtz A. The effect of insulin deprivation on fasting levels of 5000 dalton gastric inhibitory polypeptide in type 1 (insulin-dependent) diabetics. Diabet Metab 1985; 11: 364–7
  • Krarup T, Madsbad S, Moody AJ. Gastric inhibitory polypeptide in newly diagnosed ketotictypc 1 (insulin-dependent) diabetics. Acta Med Scand 1988; 223: 437–41
  • Service F J, Rizza R A, Westland R E, Hall L D, Gerich J E, Go V LW. Gastric inhibitory polypeptide in obesity and diabetes mellitus. J Clin Endocrinol Metab 1984; 58: 1133–40
  • Madsbad S, Krarup T, Regeur L, Faber O K, Binder C. Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol 1980; 95: 359–63
  • Krarup T, Madsbad S, Moody A J, Regeur L, Faber O K, Hoist J J, Sestoft L. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type 1 (insulin-dependent) diabetics. J Clin Endocrinol Metab 1983; 56: 1306–12
  • Krarup T, Madsbad S, Moody AJ. Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of Type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab 1985; 60: 120–5
  • Krarup T, Madsbad S, Regeur L, Faber O K, Tronier B. Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in Type 1 (insulin-dependent) diabetes mellitus. Acta Endocrinol 1984; 105: 221–5
  • Krarup T, Saurbrey N, Moody A J, Kuhl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 1987; 36: 677–82
  • DeFronzo RA. The triumvirate: β–cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667–87
  • Jones I R, Owens D R, Moody A J, Luzio S, Morris T., Hayes TM. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and β-cell secretion. Diabetologia 1987; 30: 707–12
  • Elahi D, Andersen D K, Muller D C, Tobin J D, Brown J C, Andres R. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging obesity, and non-insulin-dependent diabetes mellitus. Diabetes 1984; 33: 950–7
  • Groop P-H. The influence of body weight, age and glucose tolerance on the relationship between GIP secretion and beta-cell function in man. Scand J Clin Lab Invest 1989; 49: 367–79
  • Groop P-H, Fyhrquist F, Groop LC. Effect of serial test meals on plasma immunoreactive GIP in non-insulin dependent diabetic patients and non-diabetic controls. Scand J Clin Lab Invest 1985; 45: 115–22
  • Jones I R, Owens D R, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 666–77
  • Nauck M, Stöckmann F, Ebert R, Creutz-Feldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52
  • Tronier B, Deigård A, Andersen T, Madsbad S. Absence of incretin effect in obese type II and diminished effect in lean type II subjects. Diabetes Res Clin Pract 1985; 1: S568, Suppl. 1

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.